Pulmonary alveolar proteinosis: Diagnostic and therapeutic challenges

Ilaria Campo, Zamir Kadija, Francesca Mariani, Elena Paracchini, Giuseppe Rodi, Francesco Mojoli, Antonio Braschi, Maurizio Luisetti

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Pulmonary Alveolar Proteinosis (PAP) is a rare syndrome characterized by pulmonary surfactant accumulation within the alveolar spaces. It occurs with a reported prevalence of 0.1 per 100,000 individuals and in distinct clinical forms: autoimmune (previously referred to as the idiopathic form, represents the vast majority of PAP cases, and is associated with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) auto-antibodies; GMAbs), secondary (is a consequence of underlying disorders), congenital (caused by mutations in the genes encoding for the GM-CSF receptor), and PAP-like syndromes (disorders associated with surfactant gene mutations). The clinical course of PAP is variable, ranging from spontaneous remission to respiratory failure. Whole lung lavage (WLL) is the current standard treatment for PAP patients and although it is effective in the majority of cases, disease persistence is not an unusual outcome, even if disease is well controlled by WLL. In this paper we review the therapeutic strategies which have been proposed for the treatment of PAP patients and the progress which has been made in the understanding of the disease pathogenesis.

Original languageEnglish
Article number4
JournalMultidisciplinary Respiratory Medicine
Volume7
Issue number1
DOIs
Publication statusPublished - Jun 11 2012

Fingerprint

Pulmonary Alveolar Proteinosis
Bronchoalveolar Lavage
Therapeutics
Granulocyte-Macrophage Colony-Stimulating Factor Receptors
Spontaneous Remission
Pulmonary Surfactants
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Mutation
Granulocyte-Macrophage Colony-Stimulating Factor
Surface-Active Agents
Respiratory Insufficiency
Genes
Antibodies

Keywords

  • GM-CSF
  • Pulmonary alveolar proteinosis
  • WLL

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Pulmonary alveolar proteinosis : Diagnostic and therapeutic challenges. / Campo, Ilaria; Kadija, Zamir; Mariani, Francesca; Paracchini, Elena; Rodi, Giuseppe; Mojoli, Francesco; Braschi, Antonio; Luisetti, Maurizio.

In: Multidisciplinary Respiratory Medicine, Vol. 7, No. 1, 4, 11.06.2012.

Research output: Contribution to journalArticle

@article{18674e171c1d40408fe81d00780eb15c,
title = "Pulmonary alveolar proteinosis: Diagnostic and therapeutic challenges",
abstract = "Pulmonary Alveolar Proteinosis (PAP) is a rare syndrome characterized by pulmonary surfactant accumulation within the alveolar spaces. It occurs with a reported prevalence of 0.1 per 100,000 individuals and in distinct clinical forms: autoimmune (previously referred to as the idiopathic form, represents the vast majority of PAP cases, and is associated with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) auto-antibodies; GMAbs), secondary (is a consequence of underlying disorders), congenital (caused by mutations in the genes encoding for the GM-CSF receptor), and PAP-like syndromes (disorders associated with surfactant gene mutations). The clinical course of PAP is variable, ranging from spontaneous remission to respiratory failure. Whole lung lavage (WLL) is the current standard treatment for PAP patients and although it is effective in the majority of cases, disease persistence is not an unusual outcome, even if disease is well controlled by WLL. In this paper we review the therapeutic strategies which have been proposed for the treatment of PAP patients and the progress which has been made in the understanding of the disease pathogenesis.",
keywords = "GM-CSF, Pulmonary alveolar proteinosis, WLL",
author = "Ilaria Campo and Zamir Kadija and Francesca Mariani and Elena Paracchini and Giuseppe Rodi and Francesco Mojoli and Antonio Braschi and Maurizio Luisetti",
year = "2012",
month = "6",
day = "11",
doi = "10.1186/2049-6958-7-4",
language = "English",
volume = "7",
journal = "Multidisciplinary Respiratory Medicine",
issn = "1828-695X",
publisher = "BioMed Central Ltd.",
number = "1",

}

TY - JOUR

T1 - Pulmonary alveolar proteinosis

T2 - Diagnostic and therapeutic challenges

AU - Campo, Ilaria

AU - Kadija, Zamir

AU - Mariani, Francesca

AU - Paracchini, Elena

AU - Rodi, Giuseppe

AU - Mojoli, Francesco

AU - Braschi, Antonio

AU - Luisetti, Maurizio

PY - 2012/6/11

Y1 - 2012/6/11

N2 - Pulmonary Alveolar Proteinosis (PAP) is a rare syndrome characterized by pulmonary surfactant accumulation within the alveolar spaces. It occurs with a reported prevalence of 0.1 per 100,000 individuals and in distinct clinical forms: autoimmune (previously referred to as the idiopathic form, represents the vast majority of PAP cases, and is associated with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) auto-antibodies; GMAbs), secondary (is a consequence of underlying disorders), congenital (caused by mutations in the genes encoding for the GM-CSF receptor), and PAP-like syndromes (disorders associated with surfactant gene mutations). The clinical course of PAP is variable, ranging from spontaneous remission to respiratory failure. Whole lung lavage (WLL) is the current standard treatment for PAP patients and although it is effective in the majority of cases, disease persistence is not an unusual outcome, even if disease is well controlled by WLL. In this paper we review the therapeutic strategies which have been proposed for the treatment of PAP patients and the progress which has been made in the understanding of the disease pathogenesis.

AB - Pulmonary Alveolar Proteinosis (PAP) is a rare syndrome characterized by pulmonary surfactant accumulation within the alveolar spaces. It occurs with a reported prevalence of 0.1 per 100,000 individuals and in distinct clinical forms: autoimmune (previously referred to as the idiopathic form, represents the vast majority of PAP cases, and is associated with Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) auto-antibodies; GMAbs), secondary (is a consequence of underlying disorders), congenital (caused by mutations in the genes encoding for the GM-CSF receptor), and PAP-like syndromes (disorders associated with surfactant gene mutations). The clinical course of PAP is variable, ranging from spontaneous remission to respiratory failure. Whole lung lavage (WLL) is the current standard treatment for PAP patients and although it is effective in the majority of cases, disease persistence is not an unusual outcome, even if disease is well controlled by WLL. In this paper we review the therapeutic strategies which have been proposed for the treatment of PAP patients and the progress which has been made in the understanding of the disease pathogenesis.

KW - GM-CSF

KW - Pulmonary alveolar proteinosis

KW - WLL

UR - http://www.scopus.com/inward/record.url?scp=84866294614&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866294614&partnerID=8YFLogxK

U2 - 10.1186/2049-6958-7-4

DO - 10.1186/2049-6958-7-4

M3 - Article

C2 - 22958344

AN - SCOPUS:84866294614

VL - 7

JO - Multidisciplinary Respiratory Medicine

JF - Multidisciplinary Respiratory Medicine

SN - 1828-695X

IS - 1

M1 - 4

ER -